Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business

Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet